Literature DB >> 33098843

Percutaneous Closure of Patent Ductus Arteriosus in Infants 1.5 kg or Less: A Meta-Analysis.

Adrianne Rahde Bischoff1, Bonny Jasani2, Shyam K Sathanandam3, Carl Backes4, Dany E Weisz5, Patrick J McNamara6.   

Abstract

OBJECTIVE: To investigate technical success and safety of percutaneous patent ductus arteriosus closure in infants ≤1.5 kg. STUDY
DESIGN: A systematic review and meta-analysis was performed. Data sources included Scopus, Web of Science, Embase, CINAHL, Cochrane, and PubMed from inception to April 2020. Publications were included if they had a clear definition of the intervention as percutaneous patent ductus arteriosus closure in infants ≤1.5 kg. Data extraction was independently performed by multiple observers. Primary outcome was technical success and secondary outcomes were adverse events (AEs). Subgroup analysis was performed in infants ≤6.0 kg. Data were pooled by using a random-effects model.
RESULTS: We included 28 studies, including 373 infants ≤1.5 kg and 69 studies enrolling 1794 infants ≤6.0 kg. In patients ≤1.5 kg, technical success was 96% (95% CI, 93%-98%; P = .16; I2 = 23%). The overall incidence of AE was 27% (95% CI, 17%-38%; P < .001; I2 = 70%) and major AEs was 8% (95% CI, 5%-10%; P = .63; I2 = 0%). There were 5 deaths related to the procedure (2%; 95% CI, 1%-4%; P = .99; I2 = 0%); 4 of these deaths occurred in infants <0.8 kg. The probability of technical failure was inversely related to age at the time of the procedure (OR, 0.9; 95% CI, 0.830-0.974; P = .009). Weight at intervention has decreased over time and procedural success has increased.
CONCLUSIONS: Percutaneous patent ductus arteriosus closure is feasible in infants ≤1.5 kg with few major AEs. The procedural success rate is high, despite performing the intervention in smaller patients. PROSPERO REGISTRATION: CRD42020145230. Crown
Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adverse outcomes; catheter; patent ductus arteriosus; percutaneous; technical success; transcatheter

Year:  2020        PMID: 33098843     DOI: 10.1016/j.jpeds.2020.10.035

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

Review 1.  Percutaneous Closure of Patent Ductus Arteriosus.

Authors:  Megan Barcroft; Christopher McKee; Darren P Berman; Rachel A Taylor; Brian K Rivera; Charles V Smith; Jonathan L Slaughter; Afif El-Khuffash; Carl H Backes
Journal:  Clin Perinatol       Date:  2022-01-21       Impact factor: 3.430

2.  Institutional Trend in Device Selection for Transcatheter PDA Closure in Premature Infants.

Authors:  Peter Guyon; Nicole Duster; Anup Katheria; Caitlyn Heyden; Danica Griffin; Ronald Steinbergs; Andres Moreno Rojas; Kanishka Ratnayaka; Howaida G El-Said
Journal:  Pediatr Cardiol       Date:  2022-04-16       Impact factor: 1.838

Review 3.  Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider.

Authors:  Carl H Backes; Kevin D Hill; Elaine L Shelton; Jonathan L Slaughter; Tamorah R Lewis; Dany E Weisz; May Ling Mah; Shazia Bhombal; Charles V Smith; Patrick J McNamara; William E Benitz; Vidu Garg
Journal:  J Am Heart Assoc       Date:  2022-09-03       Impact factor: 6.106

4.  Use of the Medtronic Microvascular Plug 7Q for transcatheter closure of large patent ductus arteriosus in infants weighing less than 2.5 kg.

Authors:  Mohamed Al Nasef; Donnchadh O Sullivan; Li Yen Ng; Kevin P Walsh; Paul Oslizlok; Brian McCrossan; Damien Kenny; Shyam Sathanandam
Journal:  Catheter Cardiovasc Interv       Date:  2022-01-30       Impact factor: 2.585

Review 5.  Consensus Guidelines for the Prevention and Management of Periprocedural Complications of Transcatheter Patent Ductus Arteriosus Closure with the Amplatzer Piccolo Occluder in Extremely Low Birth Weight Infants.

Authors:  Shyam Sathanandam; Dan Gutfinger; Brian Morray; Darren Berman; Matthew Gillespie; Thomas Forbes; Jason N Johnson; Ruchira Garg; Sophie Malekzadeh-Milani; Alain Fraisse; Osman Baspinar; Evan M Zahn
Journal:  Pediatr Cardiol       Date:  2021-06-30       Impact factor: 1.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.